ALA 2.63% 19.5¢ arovella therapeutics limited

windshift: "Not before mid-2022. There is simply too much to do...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 13,025 Posts.
    lightbulb Created with Sketch. 782
    windshift: "Not before mid-2022. There is simply too much to do to see it done before then. Even that is tight (that's less than 2 years away). But I like the program and it is worth pursuing IMO. GLTA."

    windshift/others: Because it WILL take a LOT of time (as well as a LOT of money over time...) to pursue this most important project for SUDA, there will - JIMHO - no 'soon' strong re-rating in the near-term. In fact, I tend to believe that Suda is overvalued at present - but of course, I could be completely wrong, of course.
    Moreover, "things" could suddenly change, i.e. perhaps Mr. Hopper will find another project to inject into Suda resp. inject Suda into another project...

    Time will tell as usual.

    wasa
 
watchlist Created with Sketch. Add ALA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.